A new view on development of a Staphylococcus aureus vaccine: Insights from mice and men

Human Vaccines

Volumn 6, Issue 10, 2010, Pages 857-859

  Spellberg, Brad ^a,b   Daum, Robert ^c  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cell mediated; Humoral; Immunology; S. Aureus; Th1; Th17; Vaccine

Indexed keywords

NEUTRALIZING ANTIBODY; STAPHYLOCOCCUS VACCINE;

ADAPTIVE IMMUNITY; BACTEREMIA; CELLULAR IMMUNITY; HIGH RISK PATIENT; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; IMMUNOPATHOGENESIS; INFECTION SENSITIVITY; NONHUMAN; NOTE; STAPHYLOCOCCUS INFECTION; TH1 CELL; TH17 CELL;

ANIMALS; HUMANS; MICE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; STAPHYLOCOCCUS AUREUS;

EID: 78649375230     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.10.12469     Document Type: Note

References (24)

1. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008; 7:401-9.
2. nd ed. New York: Mosby 2001.
3. Robbins JB, Schneerson R, Horwith G, Naso R, Fattom A. Staphylococcus aureus types 5 and 8 capsular polysaccharide-protein conjugate vaccines. Am Heart J 2004; 47:593-8.
4. Fattom AI, Horwith G, Fuller S, Propst M, Naso R. Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials. Vaccine 2004; 2:880-7.
5. Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002; 46:491-6.
6. Fattom A, Fuller S, Propst M, Winston S, Muenz L, He D, et al. Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients. Vaccine 2004; 3:656-63.
7. Release P. Nabi Biopharmaceuticals Announces Results of StaphVAX(R) Confirmatory Phase III Clinical Trial. Finance.Yahoo.Com, 2005; (Accessed 2005, at http://biz.yahoo.com/prnews/051101/ nytu109.html?v=27).
8. Montgomery CP, Boyle-Vavra S, Adem PV, Lee JC, Husain AN, Clasen J, et al. Comparison of virulence in community-associated methicillin-resistant Staphylococcus aureus pulsotypes USA300 and USA400 in a rat model of pneumonia. J Infect Dis 2008; 98:561-70.
9. Inhibitex Reports Favorable Results From Aurexis Phase II Trial for the Treatment of Staph Bloodstream Infections. Inhibitex Inc., 2005; (Accessed 2005, at http://phx.corporate-ir.net/phoenix. zhtml?c=176944&p=irol- newsArticle&ID=707 322&highlight=).
10. Inhibitex Reports Top-Line Results in Phase III Study of Veronate(R). PR Newswire, April 3, 2006 (Accessed at http://www.prnewswire.com/cgi-bin/ stories.pl?ACCT=104&STORY=/www/story/04- 03-2006/0004331599&EDATE=).
11. Spellberg B, Ibrahim AS, Yeaman M, Lin L, Fu Y, Avanesian V, et al. The anti-fungal rAls3p-N vaccine protects mice against the bacterium Staphylococcus aureus. Infect Immun 2008; 6:4574-80. PMC2546811.
12. Miller LG, Perdreau-Remington F, Bayer AS, Diep B, Tan N, Bharadwa K, et al. Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation. Clin Infect Dis 2007; 4:471-82.
13. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. Jama 2007; 98:1763-71.
14. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 55:666-74.
15. Fridkin SK, Hageman JC, Morrison M, Sanza LT, Como-Sabetti K, Jernigan JA, et al. Methicillinresistant Staphylococcus aureus disease in three communities. N Engl J Med 2005; 52:1436-44.
16. th ed. Philadelphia, PA: Elsevier 2005:2321-51.
17. Laupland KB, Church DL, Mucenski M, Sutherland LR, Davies HD. Population-based study of the epidemiology of and the risk factors for invasive Staphylococcus aureus infections. J Infect Dis 2003; 87:1452-9.
18. Jensen AG, Wachmann CH, Poulsen KB, Espersen F, Scheibel J, Skinhoj PF, et al. Risk factors for hospital-acquired Staphylococcus aureus bacteremia. Arch Intern Med 1999; 59:1437-44.
19. Lin L, Ibrahim AS, Xu X, Farber JM, Avanesian V, Baquir B, et al. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 2009; 1000703. PMC2792038.
20. Ishigame H, Kakuta S, Nagai T, Kadoki M, Nambu A, Komiyama Y, et al. Differential roles of interleukin- 17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity 2009; 108-19.
21. Lin L, Ibrahim AS, Baquir B, Avanesian V, Fu Y, Spellberg B. Immunological surrogate marker of rAls3p-N vaccine-induced protection against Staphylococcus aureus. FEMS Immunol Med Microbiol 2009; PMC2801022.
22. Pachl J, Svoboda P, Jacobs F, Vandewoude K, van der Hoven B, Spronk P, et al. Randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 2006; 2:1404-13.
23. Torosantucci A, Bromuro C, Chiani P, De Bernardis F, Berti F, Galli C, et al. A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med 2005; 02:597-606.
24. Torosantucci A, Chiani P, Bromuro C, De Bernardis F, Palma AS, Liu Y, et al. Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence. PLoS ONE 2009; 5392.